| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6902742 | RECRO GAINESVILLE | Multiparticulate modified release composition |
Nov, 2019
(4 years ago) | |
| US6228398 | RECRO GAINESVILLE | Multiparticulate modified release composition |
Nov, 2019
(4 years ago) | |
| US9265760 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9433619 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9421200 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9333201 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9339499 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9326982 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10322120 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10722511 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10028946 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US10456393 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9610286 | RECRO GAINESVILLE | Treating pain in patients with hepatic impairment |
Jul, 2033
(9 years from now) | |
| US9486451 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US10092559 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9452163 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9713611 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
| US9132096 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(10 years from now) | |
Zohydro Er is owned by Recro Gainesville.
Zohydro Er contains Hydrocodone Bitartrate.
Zohydro Er has a total of 18 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zohydro Er are:
- US6902742
- US6228398
Zohydro Er was authorised for market use on 25 October, 2013.
Zohydro Er is available in capsule, extended release;oral dosage forms.
Zohydro Er can be used as treatment of pain, treatment of pain in patients with hepatic impairment.
The generics of Zohydro Er are possible to be released after 12 September, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 25, 2016 |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain in patients with hepatic impairment; Treatment of pain
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ZOHYDRO ER family patents
